DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the ACCENT MICROCELL LIMITED (ACCENTMIC) share price today?

ACCENT MICROCELL LIMITED (ACCENTMIC) is trading at ₹513.4 on the NSE, up 0.71% on the day. Source: DocStoX.

What is the PE ratio of ACCENT MICROCELL LIMITED?

ACCENT MICROCELL LIMITED has a price-to-earnings (PE) ratio of 37.3 in the Healthcare sector.

What is the market capitalisation of ACCENT MICROCELL LIMITED?

ACCENT MICROCELL LIMITED has a market capitalisation of approximately ₹0 crore.

ACCENT MICROCELL LIMITED

ACCENTMIC·NSE·Healthcare

₹513.40▲ +3.60 (+0.71%)

Healthcare · Pharmaceuticals

Debt-free and consistently profitable

Day₹504.00

₹519.35

52W₹238

₹52596%

Open

₹519.35

High

₹519.35

Low

₹504.00

Prev Close

₹509.80

Volume

16.5K

VWAP

₹511.05

Snapshot

Key fundamentals

Market Cap

₹0 Cr

P/E Ratio

37.26Expensive

P/B Ratio

4.29

EPS

₹13.78

Book Value

₹114.84

ROE

18.60%Strong

ROCE

24.00%Efficient

Dividend Yield

0.20%

Debt / Equity

0.00Low

Face Value

₹10.00

52W High

₹525.00

52W Low

₹238.00

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹155

▼ 69.7%downside

Trading at ₹513 — 70% above our estimate

BearFair valueBull

₹132₹155₹189

/100

Business quality — Solid

Growth 37Profitability 63Efficiency 40Valuation 66

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet
Fundamental red flags (Piotroski 2/9)

Strengths

Virtually debt-free balance sheet
Capital is working hard (ROCE 24%)
Promoters hold a controlling stake

Risks

Fundamental red flags (Piotroski 2/9)

How we got there

Fair value methods

Residual income

17% ROE fading to 12% over ~10 yrs, on ₹115 book

₹146

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹189

Analyst target

No analyst coverage

—

Blended fair value₹155

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Capital is working hard (ROCE 24%)
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 2/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

37.3Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

18.6%Strong

Above 15% is considered healthy for Indian equities

ROCE

24.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.00Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

—

P/B

4.29

EPS

₹13.78

Div Yield

0.20%

What changed

Recent changes

Foreign investors+0.3% stake last quarter
Promoters-2.45% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 37.3×

Growth

Strong

+52% rev CAGR

Profitability

Excellent

18.6% ROE

Financial health

Rock solid

D/E 0.00

Momentum

N/A

No technicals

Today

Trading activity

Delivery %60.6%

Turnover₹84.32L Cr

Trades31

VWAP₹511.05

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+52.5%

+39.3%

10Y

—

Profit

+94.1%

+77.3%

10Y

—

EPS

—

10Y

—

Profile

Pros

Company has reduced debt.
Company is almost debt free.
Company has delivered good profit growth of 54.3% CAGR over last 5 years

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Promoters trimmed their stake by 2.45 pts; foreign investors bought 0.33 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

53%

Promoter

Promoters

53.0%-2.45

Public

42.5%+2.17

FII / FPI

0.9%+0.33

DII

3.5%-0.05

Quarterly trend

Ownership over time

Q1 FY27

Promoter53.02%

FII0.91%

DII3.54%

Public42.53%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2012, Accent Microcell Ltd manufactures Pharmaceutical Excipients[1]